Hoth Therapeutics (HOTH) has been granted a key patent by the Japan Patent Office, expanding its global intellectual property portfolio in ...

See how small bits of non-coding RNA target mRNA for destruction and ... to various diseases by injecting manufactured dsRNA or antisense siRNA strands into cells (Whalley, 2006).

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting ...

They found their answer in antisense oligonucleotides (ASOs)--synthetic RNA fragments that can be designed to increase poison ...

RNA epigenetic modifications have uncovered as not only an intermediary structure between DNA and protein or an effector ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033, according to ...

Under his leadership, ARNAY Sciences is advancing the chemical engineering of DNA and RNA and redefining medical health by developing effective, high-quality antisense drugs. As the company continues ...

Antisense Oligonucleotides Market forecast to 2035 highlights size, emerging trends, key applications, and growth drivers shaping the future of genetic therapies.

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

I am interested in deciphering the functional role of noncoding RNA (ncRNA) in gene regulation network governing forest tree growth and development. One significant class of such ncRNA is natural ...